Ginsenoside Rb1 Decreases Injury-Induced Vascular Restenosis
Ginsenoside Rb1 Decreases Injury-Induced Vascular Restenosis
批准号:
7943144
负责人:
Wei Zhou
金额:
$14.18万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-02-29
关键词:
AgingAngioplastyAnimal ModelApolipoprotein EArterial Fatty StreakAtherosclerosisBalloon AngioplastyBlood VesselsCardiovascular DiseasesCardiovascular systemCarotid Artery InjuriesCell ProliferationCellular StressClinicalClinical ResearchCommon carotid arteryComplementary and alternative medicineCoronary arteryDevelopmentElderlyEndothelial CellsEndotheliumFamily suidaeFoundationsFree RadicalsFunctional disorderGinseng PreparationGinsenosidesHistologyHomocysteineHomocystineHumanHyperplasiaImaging TechniquesInjuryInterventionInvestigationLeadLife StyleMediatingMethodsModelingMolecularMonitorMorbidity - disease rateMusOxidative StressPatientsPeripheral Vascular DiseasesPlant RootsPlasmaPlayPopulationProceduresProductionReactive Oxygen SpeciesRecording of previous eventsRegulationRiskRisk FactorsRoleSignal PathwaySmooth Muscle MyocytesSolidSourceSuperoxidesSystemSystems AnalysisTherapeuticVasomotoraging populationalternative treatmentatherogenesisginsenoside Rb1immunoreactivityin vivoinjuredinterdisciplinary approachmigrationmolecular imagingmortalitynovel strategiesprotective effectpublic health relevanceresearch studyrestenosistreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ginseng root is one of the most widely recognized herbal supplements with increased clinical evidence of potential benefits in cardiovascular diseases. Studies have shown that ginsenosides, active constituents of ginseng, have protective roles in atherosclerotic plaque formation and various vascular injuries. We hypothesize that ginseng root and ginsenoside have protective effects against angioplasty-induced vascular damage and post-angioplasty restenosis. We recently have demonstrated that ginsenoside Rb1 (Rb1) blocks homocysteine (HCY)-induced detrimental effects on endothelial vasomotor function, free-radical production, and eNOS expression. To extend the preliminary studies, we propose a more comprehensive investigation to elucidate the molecular mechanisms, cellular effects, and in vivo influences of Rb1 on HCY- exaggerated cellular stress following vascular injury. Our central hypothesis is that Rb1 effectively blocks HCY-augmented vascular dysfunction and restenosis by maintaining a functional eNOS system and decreasing oxidative stress. Two specific aims are proposed: Specific Aim 1: Determine the molecular mechanisms of Rb1-medicated eNOS rescue and ROS suppression in HCY-induced cellular stress. Hypothesis: both eNOS dysfunction and oxidative stress play important roles in HCY-induced atherogenesis and restenosis. These two systems are intimately related, yet distinct entities. Rb1 exerts its protective effects by modulating eNOS expression and O2.- production. In this aim, we will study the eNOS system by analyzing eNOS expression, activity, and regulation in human coronary artery endothelial cells (HCAECs) (Specific Aim 1a). We will also investigate the sources of reactive oxygen species (ROS) production in HCAECs and determine whether ROS-mediated signaling pathway is involved in HCY-induced endothelial dysfunction (Specific Aims 1b). Specific Aim 2: Determine the effects of Rb1 on HCY-augmented intimal hyperplasia in a post-guide wire injured murine model. A guidewire-induced common carotid artery injury model in Apolipoprotein E deficient (ApoE-/-) mice will be used. Degree and composition of restenosis will be monitored using a molecular imaging techniques and histology methods. This application may potentially lead to a new strategy of incorporating complementary and alternative medicine to ameliorate HCY-associated cellular stress and post-angioplasty intimal hyperplasia. Development of ginseng compounds is a great opportunity given their history of therapeutic applications and recent discoveries of their molecular actions. Our application utilizes a multidisciplinary approach to explore the mechanisms and in vivo effects of Rb1. We hope that this application will establish a solid foundation for large- scale clinical research and potentially provide an alternative treatment strategy for vascular damages and restenosis.
PUBLIC HEALTH RELEVANCE: This application utilizes a comprehensive molecular, cellular, and animal model approach to investigate the effects and mechanisms of ginsenoside Rb1 on homocysteine-exaggerated vascular dysfunction. This application may potentially lead to a new strategy of incorporating complementary and alternative medicine to ameliorate risk factor-associated cellular stress. We hope that our investigation will establish a solid foundation for large-scale clinical research and provide an alternative treatment strategy for vascular restenosis in an aging population.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.jss.2008.07.005
发表时间:
2009-12
期刊:
The Journal of surgical research
影响因子:
--
作者:
[Chai H, Dong Y, Wang X, Zhou W]
通讯作者:
Zhou W
DOI:
10.1016/j.jss.2010.01.026
发表时间:
2010-07
期刊:
The Journal of surgical research
影响因子:
--
作者:
[Chai H, Schultz G, Aghaie K, Zhou W]
通讯作者:
Zhou W
Targeting LKB1-null lung adenocarcinoma with innate immune system
-
批准号:10752833
-
项目类别:
-
资助金额:$43.12万
-
财政年份:2023
-
负责人:Wei Zhou
-
依托单位:
An integrative approach to disease gene discovery combining genetic variation, gene expression, and epigenetics.
-
批准号:10581608
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2022
-
负责人:Wei Zhou
-
依托单位:
An integrative approach to disease gene discovery combining genetic variation, gene expression, and epigenetics.
-
批准号:10349878
-
项目类别:
-
资助金额:$15.97万
-
财政年份:2022
-
负责人:Wei Zhou
-
依托单位:
Role of orexin/hypocretin circuit in anesthesia and analgesia
-
批准号:10651642
-
项目类别:
-
资助金额:$19.91万
-
财政年份:2020
-
负责人:Wei Zhou
-
依托单位:
Role of orexin/hypocretin circuit in anesthesia and analgesia
-
批准号:10186780
-
项目类别:
-
资助金额:$19.91万
-
财政年份:2020
-
负责人:Wei Zhou
-
依托单位:
Role of orexin/hypocretin circuit in anesthesia and analgesia
-
批准号:10430182
-
项目类别:
-
资助金额:$19.91万
-
财政年份:2020
-
负责人:Wei Zhou
-
依托单位:
Role of orexin/hypocretin circuit in anesthesia and analgesia
-
批准号:10040369
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2020
-
负责人:Wei Zhou
-
依托单位:
PKC Epsilon in Vascular Dysfunction
-
批准号:8329950
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Wei Zhou
-
依托单位:
PKC Epsilon in Vascular Dysfunction
-
批准号:8536078
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Wei Zhou
-
依托单位:
PKC Epsilon in Vascular Dysfunction
-
批准号:8698299
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Wei Zhou
-
依托单位:
Pro-Oncogenic Role of LKB1 in NSCLC
-
批准号:8830435
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Long-term Cognitive Effects of Microembolization Associated with Carotid Stenting
-
批准号:8633341
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Long-term Cognitive Effects of Microembolization Associated with Carotid Stenting
-
批准号:8109450
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Long-term Cognitive Effects of Microembolization Associated with Carotid Stenting
-
批准号:8243541
-
项目类别:
-
资助金额:$37.68万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Pro-Oncogenic Role of LKB1 in NSCLC
-
批准号:8444654
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Long-term Cognitive Effects of Microembolization Associated with Carotid Stenting
-
批准号:8460521
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Pro-Oncogenic Role of LKB1 in NSCLC
-
批准号:8613467
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Pro-Oncogenic Role of LKB1 in NSCLC
-
批准号:8108723
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2011
-
负责人:Wei Zhou
-
依托单位:
Ginsenoside Rb1 Decreases Injury-Induced Vascular Restenosis
-
批准号:7791189
-
项目类别:
-
资助金额:$22.9万
-
财政年份:2009
-
负责人:Wei Zhou
-
依托单位:
Cell and Molecular Biology Research Program
-
批准号:10627506
-
项目类别:
-
资助金额:$5.79万
-
财政年份:2009
-
负责人:Wei Zhou
-
依托单位:
海外基金